SCHEMBL16670445

SCHEMBL16670445

COc1ccc(N(C)C(=O)C(Cc2ccccc2)NC(=O)NS(=O)(=O)c2ccccc2C)cc1C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 1/20 0.45
MMP2 P08253 1/20 0.45
MMP9 P14780 1/20 0.45
MMP8 P22894 1/20 0.45
FPR2 P25090 1/20 0.43
CYP3A4 P08684 1/20 0.42
CYP2C19 P33261 1/20 0.42
ALDH1A1 P00352 3/20 0.42
ALOX15 P16050 1/20 0.42
AVPR1B P47901 2/20 0.41
POLB P06746 2/20 0.40
NPSR1 Q6W5P4 1/20 0.40
ITGB1 P05556 1/20 0.40
ITGA4 P13612 1/20 0.40
ITGB7 P26010 1/20 0.40
GAA P10253 2/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
KDM1A O60341 1/20 0.40
MAOA P21397 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16670443 1.00 MMP1 (0.45) MMP1MMP2MMP9MMP8FPR2
SCHEMBL16670863 0.90 MMP1 (0.43) MMP1MMP2MMP9MMP8FPR2
SCHEMBL16670862 0.90 MMP1 (0.43) MMP1MMP2MMP9MMP8FPR2
SCHEMBL16669864 0.90 MMP1 (0.46) MMP1MMP2MMP9MMP8FPR2
SCHEMBL16669863 0.90 MMP1 (0.46) MMP1MMP2MMP9MMP8FPR2
SCHEMBL16670298 0.89 FPR2 (0.47) MMP1MMP2MMP9MMP8FPR2
SCHEMBL16670299 0.89 FPR2 (0.47) MMP1MMP2MMP9MMP8FPR2
SCHEMBL16670031 0.88 MMP1 (0.44) MMP1MMP2MMP9MMP8FPR2
SCHEMBL16670032 0.88 MMP1 (0.44) MMP1MMP2MMP9MMP8FPR2
SCHEMBL16669942 0.88 MMP9 (0.51) MMP1MMP2MMP9MMP8POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10035760-B2 Inhibitors of human immunodeficiency virus replication VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) 2018-07-31 US disclosed
US-20160257645-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV Healthcare UK (No.5) Limited (GB) 2016-09-08 US disclosed
EP-3060554-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION Bristol-Myers Squibb Company (US) 2016-08-31 EP disclosed
WO-2015061518-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BRISTOL-MYERS SQUIBB COMPANY (US) 2015-04-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160257645-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION EIF2AK2, POLR1E, POLR1G MMP1 3144/4885MMP2 1544/4885MMP9 2601/4885
US-10035760-B2 Inhibitors of human immunodeficiency virus replication EIF2AK2, POLR1G, POLR1E MMP1 3205/4885MMP2 1711/4885MMP9 2622/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.